TY - JOUR T1 - Predicting Remission Remains a Challenge in Patients with Juvenile Idiopathic Arthritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 552 LP - 554 DO - 10.3899/jrheum.181245 VL - 46 IS - 6 AU - STEPHANIE J.W. SHOOP-WORRALL AU - KIMME L. HYRICH Y1 - 2019/06/01 UR - http://www.jrheum.org/content/46/6/552.abstract N2 - The consequences of persistent active disease in juvenile idiopathic arthritis (JIA) include chronic pain and disability, in addition to growth disturbances and joint damage1,2. The last 2 decades have seen the development and licensing of biological therapies for JIA, revolutionizing patient care3. Now, more than ever, resolution of the signs and symptoms of JIA (i.e., remission) may be an attainable goal. However, even in cohorts of children and young people (CYP) with JIA where these newer therapies are widely available, fewer than 50% of CYP achieve remission in the first 10 years following diagnosis4.For outcomes to improve in JIA, clinicians must take advantage of the window of opportunity. This window represents a short time after diagnosis whereby early treatments may be most effective5. Thus, appropriate therapies must be used as early as possible. There is an ongoing push toward stratified or personalized medicine across specialties, including rheumatology6. If nonremission could be predicted, patients at higher risk could be managed differently, for example, with the earlier use of targeted therapies such as biologics. This would additionally minimize the risk of adverse events from exposure to unnecessary therapies that may be less successful at controlling disease in that patient. However, it is currently unclear which patients are predisposed toward a remission-like … Address correspondence to Prof. K.L. Hyrich, 2.800 Stopford Building, The University of Manchester, Oxford Road, Manchester M13 9PT, UK. E-mail: Kimme.hyrich{at}manchester.ac.uk ER -